Uncategorized Archives - Page 7 of 134

FridayOct 18, 2024 12:00 pm

Clene Inc. (NASDAQ: CLNN) Presents Lead Candidate CNM-Au8(R) Updates, Latest Achievements at Top Investor Conferences

Clene gave a fireside presentation and held one-on-one investor meetings at the 2024 Maxim Healthcare Virtual Summit on October 15. On October 30, Clene will give a presentation and participate in one-on-one meetings at The ThinkEquity Conference 2024 at the Mandarin Oriental Hotel in New York. Clene’s lead drug candidate, CNM-Au8® has been shown to restore and protect neurological function, offering new hope for patients with ALS and other neurodegenerative conditions. Clene is seeking an accelerated approval pathway for CNM-Au8 for ALS and is scheduled to have a meeting with the FDA leadership in November. Clene (NASDAQ: CLNN) and its…

ThursdayOct 10, 2024 11:15 am

Clene Inc. (NASDAQ: CLNN) Closes $7.3 Million Registered Direct Offering and Concurrent Private Placements

Proceeds from the offerings will support the company’s operations into the first quarter of 2025. Clene also amended its existing debt facility with Avenue Venture Opportunities Fund, L.P. to reduce or defer future monthly principal payments and to extend principal amortization period and the final maturity date into the first half of 2025. The company’s lead drug candidate, CNM-Au8® has been shown to restore and protect neurological function, offering new hope for patients with ALS and other neurodegenerative conditions. Clene is seeking an accelerated approval pathway for CNM-Au8 for ALS, with a meeting scheduled with the FDA before the end…

TuesdayOct 08, 2024 9:45 am

Astiva Health Inc. Integrates Key Medicare Components into Single Plan, Making It Easier to Manage Healthcare, Access Resources

This year enrollment in Medicare Advantage plans reached 32.8 million members, representing 52% of all Medicare recipients. Medicare Advantage plans typically integrate various health services under one umbrella. Astiva Health’s approach helps members manage existing health conditions and also focuses on promoting overall wellness. Over the past two decades, Medicare Advantage has transformed from a niche option into a primary choice for millions of seniors across the United States. Medicare Advantage plans bundle Part A, Part B and sometimes Part D coverage into one plan, along with often offering extra benefits that original Medicare doesn't cover. A fast-growing Medical Advantage…

FridayOct 04, 2024 11:15 am

Annovis Bio Inc. (NYSE: ANVS) Seeking to Strengthen Intellectual Property Portfolio, Protecting Multifaceted Approach for Treatment of Neurodegenerative Diseases

Annovis Bio recently filed three new patents covering combinations of buntanetap, its lead compound, with a GLP-1 agonist (such as dulaglutide/Trulicity) and with PDE5 inhibitors (such as sildenafil/Viagra), as well as a combination of all three The company believes these combinations create a broader approach to treating neurodegenerative diseases Preclinical studies have demonstrated these combinations significantly improve cognition in Alzheimer’s mouse models Combinations of buntanetap with PDE5 inhibitors and GLP-1 agonists are now ready to enter phase 3 clinical studies (buntanetap is in phase 3, and a number of PDE5 inhibitors and GLP-1 agonists are already on the market) Annovis…

WednesdaySep 25, 2024 9:00 am

Annovis Bio Inc. (NYSE: ANVS) Presented Recent Achievements and Strategic Direction at H.C. Wainwright Investment Conference

The event was attended by Annovis Founder, President and CEO Maria L. Maccecchini, Ph.D. Dr. Maccecchini discussed the company’s notable achievements and plans for the future and held a Q&A session with attendees. The company CEO also participated in an expert panel discussing innovative non-amyloid approaches in Alzheimer’s disease. Recent clinical trials of the company’s lead compound buntanetap obtained encouraging results and was shown to improve cognition in both Alzheimer’s and Parkinson’s patients. Annovis Bio (NYSE: ANVS), a late-stage clinical drug platform company pioneering transformative therapies for neurodegenerative diseases such as Alzheimer’s disease (“AD”) and Parkinson’s disease (“PD”), participated in…

TuesdaySep 24, 2024 9:45 am

Clene Inc. (NASDAQ: CLNN) to Discuss Lead Candidate CNM-Au8(R) Biomarker, Clinical Data for ALS with Food and Drug Administration Leadership

The company is seeking an accelerated approval regulatory pathway for CNM-Au8® for ALS. The FDA agreed to an in-person meeting to reevaluate Clene’s submission. Lead drug candidate CNM-Au8 has been shown to restore and protect neurological function, offering hope for patients with neurodegenerative conditions. The FDA meeting will be held before the end of November and will be attended by top FDA officials and key opinion leaders in ALS, biostatistics and biomarkers. Clene (NASDAQ: CLNN) and its wholly owned subsidiary Clene Nanomedicine Inc., a late clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases, including…

ThursdaySep 19, 2024 11:45 am

Astiva Health Enhances Medicare Open Enrollment with Tailored Care and Comprehensive Benefits

Open enrollment provides people with Medicare an opportunity to review options, make changes to coverage. Evaluating network, extra benefits can help individuals make important plan decisions. Astiva Health provides a wide range of valuable extra benefits, leading the industry with its generous grocery allowance and rebate programs, along with transportation services, fitness programs, vision and hearing care, and more. As Medicare open enrollment approaches, eligible individuals have the chance to review their healthcare options and make important decisions about their coverage. Astiva Health, a leading Medicare Advantage Prescription Drug (“MAPD”) health plan, stands out with its extensive network in Southern…

WednesdaySep 11, 2024 9:00 am

Clene Inc. (NASDAQ: CLNN) Management Presenting Recent Achievements, CNM-Au8(R) Results, at H.C. Wainwright Conference

The H.C. Wainwright 26th Annual Global Investment Conference is being held on-line and in person, Sept. 9-11. Clene management will give a virtual presentation of the company’s most recent achievements and results and will hold one-on-one investor meetings. Lead drug candidate CNM-Au8 has been shown to restore and protect neurological function, offering new hope for patients with neurodegenerative conditions. The company is seeking FDA approval to file a new drug application for CNM-Au8, using the accelerated approval pathway for treatment of ALS. Clene (NASDAQ: CLNN), a late clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to…

FridaySep 06, 2024 9:45 am

Clene Inc. (NASDAQ: CLNN) Seeks to Transform Neurodegenerative Disorder Treatments, with Rise in Prevalence and Associated Markets

With a focus on improving mitochondrial health, CNM-Au8® stands out among other therapies by targeting the nicotinamide adenine dinucleotide pathway to restore and protect neurological function. Nearly 2 million Americans are affected by amyotrophic lateral sclerosis (“ALS”), multiple sclerosis (“MS”) or Parkinson’s disease. The global therapeutics markets for neurogenerative diseases are projected to grow substantially, driven by the growing prevalence of these conditions, rising geriatric population and the emergence of new therapies. Clene is preparing Phase 3 trials of CNM-Au8 in MS and ALS. Clene (NASDAQ: CLNN), a late clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function…

WednesdaySep 04, 2024 9:45 am

Astiva Health Inc. Unveils New Community Outreach Initiative to Enhance Senior Wellness, Access to Care

The company is leveraging its extensive network of local partnerships to bring healthcare services directly into communities it serves Astiva is expanding network of activity centers, which are designed to be more than just places for medical care Astiva Health recognizes that true wellness goes beyond treating illness; it requires a proactive approach to health One of the pillars of Astiva Health’s approach to care is cultural responsiveness As the landscape of healthcare continues to shift toward more community-focused and personalized care, Astiva Health is launching a comprehensive community outreach initiative aimed at improving wellness and healthcare access for seniors across Southern…

News and publishing service for medical and biotechnology related companies

Contact us: 512.354.7000

Category: Uncategorized

Clene Inc. (NASDAQ: CLNN) Presents Lead Candidate CNM-Au8(R) Updates, Latest Achievements at Top Investor Conferences

Clene Inc. (NASDAQ: CLNN) Closes $7.3 Million Registered Direct Offering and Concurrent Private Placements

Astiva Health Inc. Integrates Key Medicare Components into Single Plan, Making It Easier to Manage Healthcare, Access Resources

Annovis Bio Inc. (NYSE: ANVS) Seeking to Strengthen Intellectual Property Portfolio, Protecting Multifaceted Approach for Treatment of Neurodegenerative Diseases

Annovis Bio Inc. (NYSE: ANVS) Presented Recent Achievements and Strategic Direction at H.C. Wainwright Investment Conference

Clene Inc. (NASDAQ: CLNN) to Discuss Lead Candidate CNM-Au8(R) Biomarker, Clinical Data for ALS with Food and Drug Administration Leadership

Astiva Health Enhances Medicare Open Enrollment with Tailored Care and Comprehensive Benefits

Clene Inc. (NASDAQ: CLNN) Management Presenting Recent Achievements, CNM-Au8(R) Results, at H.C. Wainwright Conference

Clene Inc. (NASDAQ: CLNN) Seeks to Transform Neurodegenerative Disorder Treatments, with Rise in Prevalence and Associated Markets

Astiva Health Inc. Unveils New Community Outreach Initiative to Enhance Senior Wellness, Access to Care

Official NewsWire Relationships

BioMedWire Currently Accepts

BioMedWire

Company Search

Site Search